Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04369846
Recruitment Status : Recruiting
First Posted : April 30, 2020
Last Update Posted : July 1, 2020
Sponsor:
Information provided by (Responsible Party):
Xantho Biotechnology Co., LTD

Brief Summary:
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: GM-XANTHO onitment Drug: Placebo onitment Phase 1 Phase 2

Detailed Description:
The Phase I study is randomized, double-blind, placebo-controlled, dose escalating. There will be 3 dose cohorts, 4 (up to 8) subjects will be randomized in a 3:1 (GM-XANTHO to placebo) ratio in each cohort.The total study will take at least 23 days, conducted in National Taiwan University Hospital with 2-24 healthy subjects being enrolled.The Phase IIa study is randomized, double-blind, placebo-controlled, parallel. 2:1 ratio for GM-XANTHO to placebo control. The total study will take at least 43 days, conducted in National Taiwan University Hospital with 38 Atopic Dermatitis patients being enrolled.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Other
Official Title: A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate Its Efficacy and Safety Profile in Atopic Dermatitis Patients
Actual Study Start Date : May 4, 2020
Estimated Primary Completion Date : January 1, 2022
Estimated Study Completion Date : May 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Experimental: Test drug group
The arm applies the test drug of GM-XANTHO
Drug: GM-XANTHO onitment
Onitment application
Other Name: Drawing blood

Placebo Comparator: Placebo group
The arm applies the placebo
Drug: Placebo onitment
Onitment application
Other Name: Drawing blood




Primary Outcome Measures :
  1. treatment emergent adverse events (TEAEs) [ Time Frame: 7 days for Phase I ]
    Number of treatment emergent adverse events (TEAEs) occurring during the Phase I

  2. IGA [ Time Frame: 28 days for Phase IIa ]
    Number of patients achieving IGA of 0 or 1 with a ≥2 point improvement in Phase IIa study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Phase I Number of patients achieving IGA of 0 or 1 with a ≥2 point improvement in Phase IIa study

  • Female or male, age ≥ 20 years old
  • Subjects whose body mass index (BMI) at screening is within a range of ≥ 18.5 kg/m2 and <30.0 kg/m2.

BMI = Body Weight (kg) / [Height (m) × Height (m)]2

  • Subject's medical history shows no contraindication to the test medications.
  • Subjects judged to be in good health by the investigator based upon the results of physical examinations (PEs), electrocardiogram (ECG) test, and all items of routine laboratory tests, including serum biochemistry, hematology and urinalysis, are within normal range as judged by the site. Assessment items of blood biochemistry include albumin, total protein, total bilirubin, ALP, SGOT, SGPT, BUN, serum creatinine. Assessment items of hematology tests include RBC count, WBC with differential counts, hemoglobin, hematocrit and platelet count. Assessment items of urinalysis include pH, color, appearance, gravity, erythrocyte, leukocyte, glucose, protein, ketones and nitrite.
  • Female subjects show negative pregnancy test results and all male and female subjects with child-bearing potential (between puberty and 2 years after menopause) should use at least any one of the appropriate contraception methods as shown in inclusion criteria #12 of phase IIa prior to the first study dose.
  • Subjects did not take any of the following medications in the specified durations:

    • Exposure of test sites to topical medications within 14 days prior to the application of IPs
    • Any systemically-absorbed medication (excluding vitamins, food supplements, and hormone contraceptives for birth control) within 14 days prior to the first dose of the study
    • Any enzyme inducer/inhibitor and/or known hepatic or renal clearance-altering agents within 30 days prior to the first dose of the study
  • Subjects are willing to comply with protocol-stated requirements, instructions and restrictions, followed by understanding and signing the written informed consent form.

Phase IIa

  • Female or male, age ≥ 20 years old
  • Patients who are diagnosed of atopic dermatitis based on the Hanifin and Rajka Criteria
  • Patients with IGA score between mild (2) to moderate (3) and the Eczema Area and Severity Indices (EASI) are ≤ 20
  • Patients who have body surface area of atopic dermatitis involvement ≥ 2%, ≤ 20%
  • Patients who agree discontinuation of all treatment modalities, such as topical antihistamines, topical antimicrobials, topical corticosteroid and light treatments during the study period for/on the affected site(s) (except the rescue medication prescribed by the study Investigator(s))
  • Patients who agree discontinuation of systemic corticosteroids, systemic antihistamines, and systemic immune modulating agents during the study period (except the standard medication oral antihistamine levocetirizine and rescue medication prescribed by the study Investigator(s)).
  • Patients are required to stop using treatment drugs listed in criteria #5 for at least 14 days (or longer if the treatment half-life requires so; 7 half-life should have elapsed) and treatment drugs listed in criteria #6 for 28 days before the first investigational drug dose administration.
  • Subject is judged to be in general good health (without clinically significant abnormalities) by the Investigator based on medical history, PEs, ECG, and routine laboratory tests at screening.
  • Patients who stopped immunosuppressant drugs for at least 28 days prior to the first dosing
  • Patients who have taken oral antihistamine of levocetirizine 5 mg once daily for at least 7 days before initiating the study treatment.
  • Patients who are eligible and able to participate in the study and accept to enter the study by signing written informed consent forms.
  • All male patients and female patients with child-bearing potential (between puberty and 2 years after menopause) should use at least any one of the appropriate contraception methods shown below, for during and at least 4 weeks after GM-XANTHO treatment.

    • Total abstinence [when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception].
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    • Male sterilization. For female subjects on the study, the vasectomized male partner should be the sole partner for that subject.
    • Combination of any two of the following listed methods: (d.1+d.2 or d.1+d.3, or d.2+d.3):

      • Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
      • Placement of an intrauterine device (IUD) or intrauterine system (IUS).
      • Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.

Exclusion Criteria:

Phase I:

  • Subjects with the following conditions at the application site(s) that would interfere with the IP administration, skin assessment, or reaction to IPs:

    • presence of open sores
    • obvious differences in skin color between applications sites
    • excessive hair
    • scar tissue tattoo
    • coloration
  • Subjects with any properly diagnosed disease within 30 days prior to the first dose of the study
  • Subjects with any diagnosed dermatological or allergic diseases within 180 days prior to the first study dose
  • Subjects with any clinically significant hematological, endocrine, cardiovascular, hepatic, renal, gastrointestinal, and/or pulmonary disorder; subjects with any predisposing condition that might interfere with the absorption, distribution, metabolism and excretion of drugs
  • Subjects had participated in investigational drug trials and took any investigational drug within 60 days prior to the first study dose.
  • Subjects had blood donation for more than 250 mL within 60 days or 500 mL within 90 days prior to the first study dose.
  • Subjects had a history of drug abuse or alcohol abuse according to the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) criteria.
  • Subjects cannot stop smoking and caffeine-intakes for 48 hours prior to the first study dose and during the entire study period, and 48 hours after the last dose administration of IPs.
  • Subjects who are inappropriate to participate in this study, as judged by the clinical Investigator
  • Subjects who have been tested positive for the following tests:

    • Human immunodeficiency virus (HIV)
    • Hepatitis B virus (HBV): HBsAg and anti-HBc
    • Hepatitis C virus (HCV)

Phase IIa:

  • Patients had participated in investigational drug trials and took any investigational drugs within 30 days or within 5 half-lives of the investigational drugs prior to the screening visit.
  • Patients who have any concurrent skin condition that will interfere with assessment of treatment
  • Patients who have active infection on the atopic dermatitis site(s) at baseline
  • Patients who are inevitable to engage activities involving excessive or prolonged exposure to sunlight
  • Patients who have known hypersensitivity to the study medication
  • Patients with chronic condition(s) which either is not stable or not well controlled
  • Patients having positive results for HBV, HCV or HIV screens
  • Patients who are pregnant or breast feeding
  • Patients carry history of malignancy of any organ system (other than cervical carcinoma in situ or localized prostate cancer) within 5 years prior to study entry.
  • Patients who are not suitable to participate in the trial as judged by the Investigator(s)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04369846


Contacts
Layout table for location contacts
Contact: Zoe Chen +886-2-26557790 xanthob@gmail.com

Locations
Layout table for location information
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 100225
Contact: Guan-Lieng Chen    +886-2-23560068 ext 813    guanlieng.chen@doint.com.tw   
Sponsors and Collaborators
Xantho Biotechnology Co., LTD
Layout table for additonal information
Responsible Party: Xantho Biotechnology Co., LTD
ClinicalTrials.gov Identifier: NCT04369846    
Other Study ID Numbers: XANGMXA20160505
First Posted: April 30, 2020    Key Record Dates
Last Update Posted: July 1, 2020
Last Verified: April 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases